QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ventyx-biosciences-announces-departure-of-martin-auster-as-chief-financial-officer-effective-august-30-2024-the-company-has-initiated-a-search-for-a-cfo

Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing nove...

 wells-fargo-maintains-overweight-on-ventyx-biosciences-lowers-price-target-to-11

Wells Fargo analyst Derek Archila maintains Ventyx Biosciences (NASDAQ:VTYX) with a Overweight and lowers the price target f...

 canaccord-genuity-maintains-buy-on-ventyx-biosciences-lowers-price-target-to-14

Canaccord Genuity analyst Edward Nash maintains Ventyx Biosciences (NASDAQ:VTYX) with a Buy and lowers the price target from...

 ventyx-biosciences-q2-eps-045-beats-057-estimate

Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(...

 hc-wainwright--co-reiterates-neutral-on-ventyx-biosciences-maintains-6-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Neutral and maintains $6 pri...

 ventyx-biosciences-inflammatory-bowel-disease-candidate-flunks-in-mid-stage-study-company-looks-for-partner-to-pursue-it-further

Ventyx Biosciences stock down over 24% on Monday after Phase 2 trial results for Crohn's disease drug VTX958 did not meet p...

 hc-wainwright--co-reiterates-neutral-on-ventyx-biosciences-maintains-6-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Neutral and maintains $6 pri...

 oppenheimer-maintains-outperform-on-ventyx-biosciences-lowers-price-target-to-10

Oppenheimer analyst Jeff Jones maintains Ventyx Biosciences (NASDAQ:VTYX) with a Outperform and lowers the price target from...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION